3D MEDICINES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.11 HKD | +7.99% |
|
+24.39% | +6.15% |
| 29/03 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
| 28/03 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2022 |
|---|---|
| Capitalization 1 | 8,383 |
| Enterprise Value (EV) 1 | 7,616 |
| P/E ratio | -1.67 x |
| Yield | - |
| Capitalization / Revenue | 1,47,73,952 x |
| EV / Revenue | 1,34,23,339 x |
| EV / EBITDA | -17.6 x |
| EV / FCF | -4,94,50,242 x |
| FCF Yield | -0% |
| Price to Book | 8.92 x |
| Nbr of stocks (in thousands) | 2,23,327 |
| Reference price 2 | 37.54 |
| Announcement Date | 28/04/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net sales | - | 60.26 | 567.4 |
| EBITDA 1 | -303.3 | -516.8 | -431.7 |
| EBIT 1 | -304.5 | -520.5 | -439.6 |
| Operating Margin | - | -863.81% | -77.47% |
| Earnings before Tax (EBT) 1 | -635.4 | -1,462 | -1,052 |
| Net income 1 | -635.4 | -1,434 | -1,024 |
| Net margin | - | -2,379.84% | -180.54% |
| EPS 2 | -13.93 | -36.72 | -22.52 |
| Free Cash Flow | - | -192.3 | -154 |
| FCF margin | - | -319.13% | -27.15% |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 28/11/22 | 28/11/22 | 28/04/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 |
|---|---|---|---|
| Net Debt 1 | 1,252 | 2,367 | - |
| Net Cash position 1 | - | - | 766 |
| Leverage (Debt/EBITDA) | -4.126 x | -4.58 x | - |
| Free Cash Flow | - | -192 | -154 |
| ROE (net income / shareholders' equity) | - | 82.5% | 153% |
| ROA (Net income/ Total Assets) | - | -41.8% | -23% |
| Assets 1 | - | 3,431 | 4,460 |
| Book Value Per Share 2 | -27.80 | -61.40 | 4.210 |
| Cash Flow per Share 2 | 9.080 | 21.20 | 3.110 |
| Capex 1 | 11.1 | 43.9 | 54 |
| Capex / Sales | - | 72.8% | 9.51% |
| Announcement Date | 28/11/22 | 28/11/22 | 28/04/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +6.15% | 218M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- 1244 Stock
- Financials 3D Medicines Inc.
